A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6‐month study

References

• Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int 1997;7:407–13
   PubMed Web of Science ®Google Scholar
• Divittorio G, Jackson KL, Chindalore VL, et al. Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis. Pharmacotherapy 2006;26:104–14
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden, et al. The use of multiple sites for the diagnosis of osteoporosis. Osteoporos Int 2006;10:1–8
   Google Scholar
• Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: The critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 2005;20:177–84
   PubMed Web of Science ®Google Scholar
• Seeman E, Delmas PD. Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrinol Metab 2001;12:281–3
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–41
   PubMed Web of Science ®Google Scholar
• Quattrocchi E, Kourlas H. Teriparatide: a review. Clin Ther 2004;26:841–54
   PubMed Web of Science ®Google Scholar
• Heaney RP. Advances in therapy for osteoporosis. Clin Med Res 2003;1:93–9
   PubMedGoogle Scholar
• Greenblatt D. Treatment of postmenopausal osteoporosis. Pharmacotherapy 2005;25:574–84
   PubMed Web of Science ®Google Scholar
• Body JJ. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone 2002;30:75S–9
   Google Scholar
• Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267–76
   Web of Science ®Google Scholar
• Hwang JS, Tu ST, Yang TS, et al. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 2006;17(3) doi:10.1007/s00198-005-2002-5
   Google Scholar
• Cummings SR, Chapurlat RD. What PROOF proves about calcitonin and clinical trials. Am J Med 2000;109:330–1
   PubMed Web of Science ®Google Scholar
• McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762–8
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Fraher LJ, Watson PH, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997;82:620–8
   PubMed Web of Science ®Google Scholar
• Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19:745–51
   PubMed Web of Science ®Google Scholar
• Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9–17
   PubMed Web of Science ®Google Scholar
• Crandall C. Parathyroid hormone for treatment of osteoporosis. Arch Intern Med 2002;162:2297–309
   PubMed Web of Science ®Google Scholar
• Gennari C, Chierichetti SM, Bigazzi S, et al. Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 1985;38:455–64
   Web of Science ®Google Scholar
• Thamsborg G, Storm TL, Sykulski R, et al. Effect of different doses of nasal salmon calcitonin on bone mass. Calcif Tissue Int 1991;48:302–7
   PubMed Web of Science ®Google Scholar
• Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556–61
   PubMed Web of Science ®Google Scholar
• O’Doherty DP, Bickerstaff DR, McCloskey EV, et al. A comparison of the acute effects of subcutaneous and intranasal calcitonin. Clin Sci (Lond) 1990;78:215–9
   PubMed Web of Science ®Google Scholar
• Overgaard K, Agnusdei D, Hansen MA, et al. Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1991;72:344–9
   PubMed Web of Science ®Google Scholar
• Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005;20:962–70
   PubMed Web of Science ®Google Scholar
• Chen P, Miller P, Delmas P, et al. Change in bone mineral density (BMD) and fracture risk reduction in teriparatide-treated women with osteoporosis. J Bone Miner Res 2005;20:S56–7
   Google Scholar